Christiansen, Elisabeth3; Due-Hansen, Maria E3; Urban, Christian2; Grundmann, Manuel2; Schmidt, Johannes2; Hansen, Steffen V F3; Hudson, Brian D2; Zaibi, Mohamed2; Markussen, Stine B2; Hagesaether, Ellen3; Milligan, Graeme2; Cawthorne, Michael A2; Kostenis, Evi2; Kassack, Matthias U2; Ulven, Trond3
1 Department of Physics, Chemistry and Pharmacy, Faculty of Science, SDU2 unknown3 Department of Physics, Chemistry and Pharmacy, Faculty of Science, SDU
The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucose-stimulated insulin secretion and is emerging as a new target for the treatment of type 2 diabetes. Several FFA1 agonists are known, but the majority of these suffer from high lipophilicity. We have previously reported the FFA1 agonist 3 (TUG-424). We here describe the continued structure-activity exploration and optimization of this compound series, leading to the discovery of the more potent agonist 40, a compound with low lipophilicity, excellent in vitro metabolic stability and permeability, complete oral bioavailability, and appreciable efficacy on glucose tolerance in mice.
Journal of Medicinal Chemistry, 2013, Vol 56, Issue 3, p. 982-92